Clinical Cancer Research: the Past, Present and the Future

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2014 Sep 24

PMID 25245981

Citations 16

Authors

Vincent T DeVita Jr

Alexander M M Eggermont

Samuel Hellman

David J Kerr

Affiliations

Soon will be listed here.

Abstract

In the past decade, we have witnessed unprecedented changes and some remarkable advances that have enabled true personalized medicine. Nevertheless, many challenges in clinical cancer research remain and need to be overcome if we are to witness similar progress in the next decade. Such hurdles include, but are not limited to, clinical development and testing of multiple agents in combination, design of clinical trials to best accommodate the ever increasing knowledge of heterogeneity of the disease, regulatory challenges relating to drug development and trial design, and funding for basic research. With this in mind, we asked four leading cancer researchers from around the world, and who have been associated with the journal since its launch in November 2004 what, in their opinion, we have learnt over the past 10 years and how we should progress in the next 10 years.

Citing Articles

Surgery Combined with Local Implantation of Doxorubicin-Functionalized Hydroxyapatite Halts Tumor Growth and Prevents Bone Destruction in an Aggressive Osteosarcoma.

Liu Y, Corbascio T, Huang J, Engellau J, Lidgren L, Tagil M J Funct Biomater. 2024; 15(8).

PMID: 39194669 PMC: 11355297. DOI: 10.3390/jfb15080232.

Ultrasensitive Detection of MicroRNA in Human Saliva via Rolling Circle Amplification Using a DNA-Decorated Graphene Oxide Sensor.

Pitikultham P, Putnin T, Pimalai D, Sathirapongsasuti N, Kitiyakara C, Jiang Q ACS Omega. 2023; 8(17):15266-15275.

PMID: 37151566 PMC: 10157686. DOI: 10.1021/acsomega.3c00411.

Synthesis of Silver Nano Particles Using Myricetin and the In-Vitro Assessment of Anti-Colorectal Cancer Activity: In-Silico Integration.

Anwer S, Mobashir M, Fantoukh O, Khan B, Imtiyaz K, Naqvi I Int J Mol Sci. 2022; 23(19).

PMID: 36232319 PMC: 9570303. DOI: 10.3390/ijms231911024.

ID-Checker Technology for the Highly Selective Macroscale Delivery of Anticancer Agents to the Cancer Cells.

Song K, Balasaheb Nimse S, Kim J, Warkad S, Kim T J Med Chem. 2022; 65(19):12883-12894.

PMID: 36194724 PMC: 9575670. DOI: 10.1021/acs.jmedchem.2c00646.

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy.

Recondo G, Mahjoubi L, Maillard A, Loriot Y, Bigot L, Facchinetti F NPJ Precis Oncol. 2020; 4:27.

PMID: 32964129 PMC: 7478969. DOI: 10.1038/s41698-020-00130-7.

References

Ascierto P, Simeone E, Sznol M, Fu Y, Melero I . Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010; 37(5):508-16. DOI: 10.1053/j.seminoncol.2010.09.008. View

Houlston R, Webb E, Broderick P, Pittman A, Di Bernardo M, Lubbe S . Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet. 2008; 40(12):1426-35. PMC: 2836775. DOI: 10.1038/ng.262. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

Edwards A, Bountra C, Kerr D, Willson T . Open access chemical and clinical probes to support drug discovery. Nat Chem Biol. 2009; 5(7):436-40. DOI: 10.1038/nchembio0709-436. View

Topalian S, Sznol M, Mcdermott D, Kluger H, Carvajal R, Sharfman W . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32(10):1020-30. PMC: 4811023. DOI: 10.1200/JCO.2013.53.0105. View

La Thangue N, Kerr D . Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol. 2011; 8(10):587-96. DOI: 10.1038/nrclinonc.2011.121. View

Eggermont A, Spatz A, Robert C . Cutaneous melanoma. Lancet. 2013; 383(9919):816-27. DOI: 10.1016/S0140-6736(13)60802-8. View

Kraman M, Bambrough P, Arnold J, Roberts E, Magiera L, Jones J . Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010; 330(6005):827-30. DOI: 10.1126/science.1195300. View

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

10.

Heimann R, Hellman S . Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol. 2000; 18(3):591-9. DOI: 10.1200/JCO.2000.18.3.591. View

11.

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

12.

Shaw A, Yeap B, Solomon B, Riely G, Gainor J, Engelman J . Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011; 12(11):1004-12. PMC: 3328296. DOI: 10.1016/S1470-2045(11)70232-7. View

13.

Simeone E, Ascierto P . Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol. 2012; 9(3):241-7. DOI: 10.3109/1547691X.2012.678021. View

14.

Lacombe D, Tejpar S, Salgado R, Cardoso F, Golfinopoulos V, Aust D . European perspective for effective cancer drug development. Nat Rev Clin Oncol. 2014; 11(8):492-8. DOI: 10.1038/nrclinonc.2014.98. View

15.

Domingo E, Church D, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E . Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013; 31(34):4297-305. DOI: 10.1200/JCO.2013.50.0322. View

16.

Lussier Y, Khodarev N, Regan K, Corbin K, Li H, Ganai S . Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141. PMC: 3518475. DOI: 10.1371/journal.pone.0050141. View

17.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A . Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003; 300(5622):1155-9. DOI: 10.1126/science.1082504. View

20.

Ward P, Thompson C . Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21(3):297-308. PMC: 3311998. DOI: 10.1016/j.ccr.2012.02.014. View